PharmAust recruits first dogs for anti-cancer drug trial
Pet owners have rallied to help ASX-listed PharmAust start to evaluate the effects of its newly formulated anti-cancer drug, Monepantel on dogs suffering from B-cell lymphoma in a planned phase IIb clinical trial. The Perth-based company, who hopes to further substantiate Monepantel’s tumour-reduction qualities, says several hounds have already been successfully recruited and
PharmAust recruits first dogs for anti-cancer drug trial
Pet owners have rallied to help ASX-listed PharmAust start to evaluate the effects of its newly formulated anti-cancer drug, Monepantel on dogs suffering from B-cell lymphoma in a planned phase IIb clinical trial. The Perth-based company, who hopes to further substantiate Monepantel’s tumour-reduction qualities, says several hounds have already been successfully recruited and